Stephens analyst Scott Fidel raised the firm’s price target on Tenet Healthcare to $60 from $57 and keeps an Equal Weight rating on the shares following the release of Q4 results and issuance of 2023 guidance. Though Tenet acknowledged that the second SCD development transaction is a year behind initial expectations in its earnings ramp, this "already likely seemed clear to the Street based on the past few quarterly updates," the firm said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare sees 2023 adjusted EPS $4.68-$5.85 vs. $7.58 in 2022
- Tenet Healthcare reports Q4 adjusted EPS $1.96 vs. $2.70 a year ago
- Tenet options imply 7.4% move in share price post-earnings
- 3 Stocks to Buy Today, 1/27/2023, According to Top Analysts
- Tenet Healthcare CFO Daniel Cancelmi retiring at year-end